Page results
-
The COVID Medicines Delivery Unit (CMDU gives new COVID-19 treatments for patients at highest risk in the community from the NCL sector. These treatments involve intravenous infustion of neutralising monoclonal antibodies (nMABs) or oral antiviral treatments, which are given to high-risk patients who have had a positive PCR test.
-
University College Hospital is one of only eight centres in London that has a Hyper-acute Stroke Unit or a HASU as they are known.
-
The TB network for north central London aims to reduce the capital’s high number of new cases and making it easier for patients to receive treatment.
-
This booklet explains what you can expect during recovery from your autologous stem cell transplant.
-
UCLH has a comprehensive service for the assessment and treatment of patients with pleural disease.
-
In partnership with Camden MSK, our department has agreed to provide ultrasound-guided joint and soft tissue injections to patients referred by the Camden community MSK services.
-
Anaemia is a condition in which the body has fewer red blood cells, or have less haemoglobin in the red blood cells, than normal. Patients who may have anaemia can be referred to general haematology by GPs and hospital doctors.
-
UCLH treats a range of red cell blood disorders and anaemias.
-
A clinic for neurology patients with long COVID
-
The UCLH post-COVID service is the lead provider for North Central London (NCL) and works with borough based services to provide support and assessment for patients with ongoing symptoms (long covid) following COVID-19 infection.
File results
-
FOI201746 Contact details for the IT integration manager
-
FOI201749 Contact details for heads of midwifery, neonatal services, bereavement services
-
FOI/2023/0594 - Asthma Treatment
-
FOI201753 Female genital mutilaton
-
FOI201756 Cardiology catheteristation laboratory
-
NIHR Patient Research Experience Survey 2022-2023
-
FOI/2023/0516 - Maternity management system
-
FOI/2023/0542 - Pulmonary rehabilitation (PR)
-
FOI/2023/0523 - Treatment on Nivolumab
-
FOI/2023/0537 - Agency usage for the Occupational Therapy